GPRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Green Plains Inc (GPRE) is not a strong buy at this moment for a beginner investor with a long-term focus. While the stock has some positive catalysts, including recent analyst upgrades and bullish technical indicators, the company's poor financial performance in the latest quarter and lack of recent news or significant trading trends make it a less compelling investment right now. Holding off for more clarity on financial improvement or stronger catalysts would be prudent.
The technical indicators for GPRE are moderately bullish. The MACD is positive and expanding, the RSI is neutral, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 14.413, with resistance levels at 15.217 and 15.714. However, the RSI at 79.136 is approaching overbought territory, which could indicate limited upside in the short term.
Analysts have recently upgraded the stock, with price targets raised to $16-$17, citing strong operational execution and potential for sustained earnings growth.
Bullish technical indicators, including positive MACD and moving averages.
Bullish sentiment in the options market, as indicated by low put-call ratios.
Poor financial performance in Q4 2025, with significant YoY declines in revenue (-26.57%), net income (-121.73%), EPS (-119.77%), and gross margin (-248.09%).
Lack of recent news or event-driven catalysts.
No significant trading trends from hedge funds or insiders.
Green Plains Inc reported disappointing financial results for Q4 2025. Revenue dropped to $428.85M (-26.57% YoY), net income fell to $11.94M (-121.73% YoY), and EPS declined to $0.17 (-119.77% YoY). Gross margin also dropped significantly to 3.88% (-248.09% YoY). The company's financials indicate a challenging operating environment and declining profitability.
Analysts have recently upgraded GPRE, with Stephens raising its price target to $17 (from $10) and Oppenheimer raising it to $16 (from $14). The upgrades are based on improved operational execution and potential for sustained earnings growth. However, UBS maintains a Neutral rating with a lower price target of $12, reflecting mixed sentiment among analysts.
